Gilead Sciences has completed its previously announced $4.9 billion acquisition of Forty Seven, a clinical-stage immuno-oncology company based in California. The immuno-oncology company has been acquired by the US biotech company for $95.50 per share in cash to become the latter’s fully-owned subsidiary. Forty Seven will be delisted from the Nasdaq Global Select Market. The […]
Gilead Sciences acquisition of Forty Seven : US biotech company Gilead Sciences has signed an all-cash deal worth around $4.9 billion to acquire Forty Seven, a clinical-stage immuno-oncology company based in California, as per the latest pharma acquisition news. The immuno-oncology company is being acquired by Gilead Sciences for $95.50 per share in cash. Through […]
BTX-A51 phase 1 trial : US biotech company BioTheryX has initiated patient dosing in its first clinical program of its small molecule BTX-A51 in patients having relapsed/refractory acute myeloid leukemia (AML), and also in high-risk myelodysplastic syndrome patients. The phase 1 clinical trial of BTX-A51 will assess the safety, pharmacokinetics, and tolerability of the oral […]
Trovagene, a California-based cancer research company, has announced the successful completion of the second dosing cohort in its Phase 1b/2 trial investigating the Onvansertib-decitabine combination for treating acute myeloid leukaemia (AML). This trial aims to assess the efficacy and safety of Onvansertib, a selective oral Polo-like Kinase 1 (PLK1) inhibitor, when used in conjunction with […]
Cantex Pharmaceuticals, a Florida-based biotechnology company, has achieved a significant milestone by securing Fast Track designation from the US Food and Drug Administration (FDA) for its innovative acute myeloid leukemia (AML) drug, CX-01. This designation is specifically for the treatment of patients over 60 years old undergoing induction therapy for newly diagnosed AML. CX-01 is […]
Tolero Pharmaceuticals has entered into a clinical research collaboration with AbbVie to explore the potential of combining their respective drugs, alvocidib and venetoclax, for the treatment of relapsed/refractory acute myeloid leukemia (AML). This innovative partnership aims to harness the synergistic effects of these drugs to enhance treatment efficacy in AML, a notoriously difficult-to-treat cancer. Alvocidib, […]
The US Food and Drug Administration (FDA) has granted approval to Agios Pharmaceuticals for Tibsovo (ivosidenib), designed for the treatment of acute myeloid leukemia (AML) in patients exhibiting specific genetic mutations and whose condition is either relapsed or refractory. This marks a significant advancement in the targeted therapy landscape for AML. Tibsovo, an isocitrate dehydrogenase-1 […]
The US Food and Drug Administration (FDA) has granted approval to Agios Pharmaceuticals’ TIBSOVO (ivosidenib) for the treatment of adult patients with acute myeloid leukemia (AML) who have relapsed or refractory conditions and are confirmed to have an isocitrate dehydrogenase-1 (IDH1) mutation. This approval marks a significant advancement in targeted cancer therapy, offering new hope […]
The blood cancer drug for elderly patients, sapacitabine (CYC682) developed by New Jersey based Cyclacel Pharmaceuticals has failed to meet its objective in a crucial phase 3 study.
Cyclacel Pharmaceuticals, a New Jersey-based biopharmaceutical company, announced that its experimental blood cancer drug, sapacitabine (CYC682), did not meet the primary endpoint in the pivotal phase 3 SEAMLESS study. The trial aimed to evaluate the effectiveness of sapacitabine in elderly patients over 70 years old who are newly diagnosed with acute myeloid leukemia (AML) and […]